Abstract: Lipid-lowering therapy has been proven to reduce macrovascular complications of type 2 diabetes. Xuezhikang is an extract of cholestin and has a markedly modulating effect on lipids, but the effect of xuezhikang on reducing coronary events in diabetic patients with coronary heart disease (CHD) is less clear. A total of 591 diabetic patients with CHD were randomized to the xuezhikang group (n = 306) and the placebo group (n = 285). During the average 4 years of follow-up, there were 28 cases of CHD events (9.2%) in the xuezhikang group and 53 cases (18.6%) in the placebo group. Risk reduction for CHD events was 50.8% (P , 0.001) by xuezhikang treatment. Xuezhikang decreased the risk of non-fatal MI by 63.8%, fatal MI by 58.5%, CHD sudden death by 26.9%, and other CHD death by 53.4%. CHD death totaled to 21 cases in the xuezhikang group (6.9%) and 35 cases in the placebo group (12.3%), indicating that xuezhikang significantly decreased the risk of CHD death by 44.1% (P , 0.05). Seventy-two patients died from various causes, among which there were 27 patients in the xuezhikang group and 45 patients in the placebo group. The risk for all-cause death was 44.1% lower in the xuezhikang group than in the placebo group (P , 0.01). This investigation demonstrates that xuezhikang therapy can be effective on reduction of cardiovascular events in diabetic patients with CHD with a reliable safety.
T ype 2 diabetes is associated with a 2-fold to 3-fold risk of death from coronary heart disease (CHD) compared with nondiabetic subjects. 1 Cardiovascular diseases (CVD) are the major causes of mortality for individuals with type 2 diabetes. 2 Reducing hyperglycemia, though effective in reducing microvascular complications, has not been proven to significantly reduce the macrovascular burden of type 2 diabetes. Prevention of CVD has therefore focused on controlling other aspects of CVD risks in patients with type 2 diabetes, including lipid management. Recently, 3 lipid-lowering trials incorporating substantial numbers of diabetic patients have been reported. In the Heart Protection Study (HPS), 3 substantial benefits of lipidlowering were demonstrated in a cohort of 5963 diabetic subjects, both in the presence (51%) and absence (49%) of established cardiovascular disease. In the Collaborative Atorvastatin Diabetes Study (CARDS), 2838 subjects with type 2 diabetes who did not have established CVD were randomly assigned to receive atorvastatin or placebo, 4 which showed that statin treatment significantly reduced the composite primary end point of major cardiovascular events by 37%. In AngloScandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA), reduction in cardiovascular events with atorvastatin was also observed in 2532 patients with type 2 diabetes. 5 Xuezhikang is an extract of cholestin that has been approved by the US Food and Drug Administration (FDA) as a Chinese red-yeast rice dietary supplement. 6 It contains a family of monacolin-related substances, one of which is a naturally occurring lovastatin, in addition to unsaturated fatty acids and other substances. 6, 7 Xuezhikang has been reported to have marked modulating effects on lipids. 6, 7 The China Coronary Secondary Prevention Study (CCSPS) 8 is a multicenter trial designed to compare the effects of xuezhikang and placebo on reducing CVD events in 4870 patients who had a history of myocardial infarction. This report presents a detailed subgroup analysis of the 591 diabetic participants.
MATERIALS AND METHODS

Subjects
The study design, organization, measurements, end points, rational, power calculations, recruitment rates, and some baseline characteristics of the CCSPS trial had been published previously. 8 Patients eligible for the CCSPS study were men and women with acute myocardial infarction (AMI) between 28 days and 5 years before hospitalization. Patients were age 18 to 75 years at randomization. They had plasma total cholesterol levels of 4.40 to 6.47 mmol/L (170 to 250/dL) and triglyceride levels of less than 4.52 mmol/L (400 mg/dL).
There were 591 patients with type 2 diabetes out of total of 4870 registry patients in CCSPS study. Type 2 diabetes diagnoses were based on the criteria adopted by the American Diabetes Association (ADA) in 1997. 9 
Recruitment and Follow-Up
The CCSPS study was a multicenter, randomized, double blind, placebo-controlled clinical trial. Patients were recruited from 65 participating centers in 19 provinces across China. Patients were recruited between November 1996 and December 2000. Eligibility criteria were established, and written informed consent was obtained. The patients were randomly assigned to receive either 0.6 g of xuezhikang or matching placebo twice daily. The patients' usual care, including medications for coronary heart disease (CHD), hypertension, and other complications, continued, whereas patients were not allowed to take other lipid-lowering drugs during the entire study period. All patients maintained a stable diet and lifestyle during follow-up. Routine visits were scheduled 6 to 8 weeks later after randomization and every 6 months thereafter to monitor clinical events. The primary objective of the study was to assess the efficacy of xuezhikang on reducing recurrent CHD events, including fatal or nonfatal myocardial infarction, sudden CHD death, and other death due to coronary heart disease. Other registered events were the occurrence of stroke and other cerebrovascular events, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), cancer, suicide, all-cause death, and drug-adverse events, including symptom and abnormal laboratory finding.
Statistical Analyses
Statistical analyses were performed using SPSS 11.5 statistical software. The data of the categorical variables were described as count and percentage. Comparisons of categorical variables between groups were performed by x 2 test. Numerical data were presented as mean 6 SD, and comparisons between groups were analyzed by t test. Differences were considered significant at a value of P , 0.05 for all tests.
RESULTS
All the 591 patients with type 2 diabetes were randomly assigned to the xuezhikang group (n = 306) and the placebo group (n = 285). The average follow-up period was 4 years, and the longest period was 7 years. Baseline characteristics and lipid changes during the treatment of the patients are shown in Tables 1 and 2 . Both groups were similar in regard to gender, age, body mass index (BMI), blood pressure, heart rate, fasting blood glucose, and fasting serum lipids. Furthermore, there were no significant differences between the 2 groups in history of smoking, alcohol consumption, hypertension, and use of medications such as aspirin, b-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitor, and nitrates. Total cholesterol (TC), triglyceride (TG), and low density lipoprotein-cholesterol (LDL-C) were significantly reduced during xuezhikang treatment.
CHD Events
There were significant differences in incidence of CHD events between the 2 groups after 1 year of follow-up. During the average 4 years of follow-up, 81 cases of CHD events occurred in all the 591 subjects, among which there were 28 cases (9.2%) in the xuezhikang group and 53 cases (18.6%) in the placebo group. Risk reduction for CHD events was 50.8% (P , 0.001) by xuezhikang treatment. Xuezhikang decreased the risk of non-fatal MI by 63.8% (P , 0.05), fatal MI by 58.5% [not significant (NS)], CHD sudden death by 26.9% (NS), and other CHD death by 53.4% (NS). CHD death totaled to 21 cases in the xuezhikang group (6.9%) and 35 cases in the placebo group (12.3%), indicating that xuezhikang significantly decreased the risk of CHD death by 44.1% (P , 0.05) ( Table 3 ).
Death Events
The beneficial effect of xuezhikang on mortality could be observed after 1 year of treatment. During the period of follow-up, 72 patients died from various causes, among which there were 27 patients in the xuezhikang group and 45 patients in the placebo group. The risk for all-cause death was 44.1% lower in the xuezhikang group than in the placebo group (P , 0.01). In addition to CHD death, 1 patient in each group died from other cardiovascular disease. There were 3 cases of fatal stroke in the xuezhikang group and 6 in the placebo group. Two patients in the xuezhikang group and 3 in the placebo group suffered other-cause death (Table 3 ).
Other Common Events
Other common events in this study included malignancies, stroke, and need for PCI/ CABG. During the follow-up, 65 cases of other common events occurred in all 591 subjects. Thirty patients in the xuezhikang group and 35 in the placebo group suffered other common events. The risk for other common events was 20.2% lower in the xuezhikang group compared with the placebo group; however, this did not reach statistically significant difference.
Comparison of Patients With and Without Diabetes
In addition to 591 patients with diabetes, 4279 CHD patients without diabetes were included in CCSPS. The incidence of CHD events and total mortality were 7.3% and 5.7%, respectively, in patients without diabetes, both of which are significantly lower than in patients with diabetes (both P , 0.0001). Similarly, rate of common events, including malignancies, stroke, and need for PCI/CABG, was 8.1% in patients without diabetes, which was also lower than that in patients with diabetes. Treatment with xuezhikang decreased the incidence of CHD events by 50.8% and total mortality by 44.1% in patients with diabetes, whereas the corresponding data were 43.9% and 30.2%, respectively, in patients without diabetes. It seemed likely that patients with diabetes could gain more beneficial effects from xuezhikang treatment with respect to CHD events and total mortality.
Clinical Adverse Events
Clinical adverse events were rare and comparable in both xuezhikang and the placebo group. There were 5 reported adverse events in the xuezhikang group, including 2 cases with gastrointestinal disorders, 2 cases with edema, and 1 case with mental-neurological symptoms. One patient was reported to have erectile dysfunction in the placebo group.
Laboratory Abnormalities
In CHD patients with type 2 diabetes, 3 patients in the xuezhikang group and 1 patient in the placebo group experienced significant (3 times upper limit of normal) elevation of serum glutamic-pyruvic transaminase (GPT). Similarly, 26 patients in the xuezhikang group and 19 patients in the placebo group were reported to have elevated blood urea nitrogen (BUN) beyond the upper limit of normal. Both of the laboratory abnormalities mentioned above did not reach statistically significant differences between the 2 groups. Serum creatinine was observed to increase beyond the upper limit of normal among 21 patients treated with xuezhikang and 7 patients treated with placebo, which showed significant difference between the 2 groups (P , 0.05). No patient in both groups experienced significant elevations (5 times the upper limit of normal) of serum creatine phosphokinase or elevations (2 times the upper limit of normal) of BUN or serum creatinine.
DISCUSSION
This study demonstrated that the beneficial effects and safety of a 1200 mg daily dose of xuzhikang on cardiocerebral vascular disease, including CHD events, stroke, and revascularization, were clear in CHD patients with diabetes by average 4 years of treatment. CHD event reduction is already apparent within 1 year of xuzhikang treatment. This study is consistent with other studies about secondary prevention of CHD events with statins in diabetic patients with CHD. In the LIPID and CARE trials, the high risk of recurrent coronary events among diabetic patients with CHD can be substantially reduced by pravastatin treatment. 10, 11 In the 4S Study, simvastatin therapy improved the prognosis of patients with DM and known CHD. 12 It is important to emphasize that this is the first study to demonstrate the reduction of coronary events by xuezhikang in diabetic patients with CHD, although the lipid-modulating and non-lipid-modulating effects of xuezhikang have been presented in other investigations. [13] [14] [15] The risk of reoccurred CHD events and death events was higher among CHD patients with diabetes than among in patients without diabetes in this study. After xuezhikang treatment, the incidences of CHD events and death events among diabetic patients with CHD were reduced significantly. Over 4 years of follow-up, xuezhikang therapy can prevent 94 CHD events, including nonfatal AMI, and 70 total death events per 1000 treated patients with diabetes, which suggests that xuezhikang treatment can improve the life quality and survival rate in diabetic patients with CHD.
The lipid-lowering effect of xuezhikang was modest in this study. During 4 years of follow-up, xuezhikang decreased the serum levels of TC and LDL-C by 10.5% and 16.9%, respectively. This may be partially explained by the fact that the daily dose of xuezhikang is only comparable to 10 mg of lovastatin. 7 Additionally, the including criteria of serum TC was 170 to 250 mg/dL in CCSPS, which was adopted according to the serum lipid level of the majority of Chinese CHD patients. 7 So the CCSPS group has relatively low baseline serum lipid levels, which were close to the normal values of western countries. This may also partly explain the modest effect of xuezhikang on serum lipids.
Compared with other large-scale CHD secondary prevention studies with statins, such as LIPID, CARE, and 4S, the baseline levels of serum cholesterol were the lowest in CCSPS population. Our subgroup analysis found that xuezhikang significantly decreased the incidence of CHD events and total mortality, suggesting that patients with CHD and diabetes can gain benefits from a regular dose of xuezhikang treatment, even when their baseline cholesterol levels are relatively low. What is the mechanism underlying the beneficial effects on secondary prevention of CHD events with xuezhikang? In this study, the reduction in CHD risk could not be explained only by lipid-modulating effect alone because the lipid-modulating effect was modest. Like statins, xuezhikang has also been demonstrated to have other beneficial effects beyond cholesterol-lowering. We found that xuezhikang could significantly reduce serum C-reactive protein (CRP) level and improve endothelium-dependent vasodilatation in patients with CHD.
14,15 So attention should be drawn to the possible inhibition of inflammation and protection of endothelial function as the mechanisms of xuezhikang action. Additionally, xuezhikang, as a modern Chinese medicine, might have other components besides naturally occurring lovastatin that exert beneficial effects on cardiovascular system; these possible effects require study.
In this study the clinical side effect did not significantly increase in xuezhikang-treated diabetic patients with CHD. With respect to laboratory safety index, more patients have increased serum creatinine levels beyond the upper limit of normal in the xuezhikang group than those in the control group. However, there was no patient whose serum creatinine level elevated beyond 2 times the upper limit of normal in both groups. There was no statistical significance of all safety indexes between the xuezhikang-treated and non-treated patients.
In conclusion, this investigation demonstrates that xuezhikang therapy can be effective in reducing cardiovascular events in diabetic patients with CHD with a reliable safety.
